{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:54:47Z","timestamp":1782762887433,"version":"3.54.5"},"reference-count":56,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["Z01 BK 04010-11"],"award-info":[{"award-number":["Z01 BK 04010-11"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.vaccine.2023.12.052","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T02:52:29Z","timestamp":1703299949000},"page":"608-619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1366-1900","authenticated-orcid":false,"given":"Alla","family":"Kachko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7266-3928","authenticated-orcid":false,"given":"Prabhuanand","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-6041","authenticated-orcid":false,"given":"Shufeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7771-6467","authenticated-orcid":false,"given":"Jaekwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rotstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5633-2950","authenticated-orcid":false,"given":"Charles B.","family":"Stauft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4005-448X","authenticated-orcid":false,"given":"Sylvie","family":"Chabot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Rajasagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4319-2531","authenticated-orcid":false,"given":"Yangqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8983-1721","authenticated-orcid":false,"given":"Tony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.12.052_b0005","unstructured":"EMA. Authorised COVID-19 vaccines. European Medicines Agency; 2020. Last accessed November 2023. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines#authorised-covid-19-vaccines-section."},{"key":"10.1016\/j.vaccine.2023.12.052_b0010","unstructured":"FDA US. COVID-19 Vaccines. U.S. Food and Drug Administration; 2020. Last accessed November, 2023. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/covid-19-vaccines."},{"key":"10.1016\/j.vaccine.2023.12.052_b0015","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.12.052_b0020","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1016\/j.vaccine.2013.02.064","article-title":"Utility of the Sindbis replicon system as an Env-targeted HIV vaccine","volume":"31","author":"Center","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.12.052_b0025","doi-asserted-by":"crossref","first-page":"11371","DOI":"10.1073\/pnas.93.21.11371","article-title":"Alphavirus-based expression vectors: strategies and applications","volume":"93","author":"Frolov","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.12.052_b0030","article-title":"Coatsome-replicon vehicles: self-replicating RNA vaccines against infectious diseases","volume":"49","author":"Demoulins","year":"2023","journal-title":"Nanomedicine"},{"key":"10.1016\/j.vaccine.2023.12.052_b0035","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1128\/JVI.77.19.10394-10403.2003","article-title":"An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector","volume":"77","author":"Perri","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0040","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1038\/s41598-021-82498-5","article-title":"DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice","volume":"11","author":"Szurgot","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.052_b0045","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1128\/jvi.67.11.6439-6446.1993","article-title":"Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs","volume":"67","author":"Bredenbeek","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0050","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","article-title":"A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models","volume":"30","author":"Maruggi","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2023.12.052_b0055","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2023.12.052_b0060","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.052_b0065","doi-asserted-by":"crossref","first-page":"E7348","DOI":"10.1073\/pnas.1707304114","article-title":"Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen","volume":"114","author":"Pallesen","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.12.052_b0070","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.12.052_b0075","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.052_b0080","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","article-title":"Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action","volume":"6","author":"Heinz","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2023.12.052_b0085","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","article-title":"Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus","volume":"81","author":"McCray","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0090","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1038\/s41467-020-19891-7","article-title":"Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice","volume":"11","author":"Oladunni","year":"2020","journal-title":"Nat Commun"},{"issue":"1070\u201385","key":"10.1016\/j.vaccine.2023.12.052_b0095","first-page":"e12","article-title":"A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice","volume":"183","author":"Leist","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.052_b0100","article-title":"Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions","author":"Pierre","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2023.12.052_b0105","article-title":"Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge","author":"Muruato","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.vaccine.2023.12.052_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001284","article-title":"Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge","volume":"19","author":"Muruato","year":"2021","journal-title":"PLoS Biol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0115","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301689120","article-title":"SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates","volume":"120","author":"Bader","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.12.052_b0120","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.4049\/jimmunol.181.9.6337","article-title":"Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV","volume":"181","author":"Yasui","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0125","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1128\/JVI.00983-14","article-title":"Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB\/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine","volume":"88","author":"Iwata-Yoshikawa","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0130","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.12.052_b0135","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4049\/immunohorizons.2200020","article-title":"Prophylactic vaccine targeting TLR3 on dendritic cells ameliorates eosinophilic pneumonia in a mouse SARS-CoV infection model","volume":"6","author":"Iwata-Yoshikawa","year":"2022","journal-title":"Immunohorizons"},{"key":"10.1016\/j.vaccine.2023.12.052_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004757","article-title":"RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets","volume":"11","author":"Knudson","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2023.12.052_b0145","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.932408","article-title":"Vaccine-associated enhanced disease in humans and animal models: lessons and challenges for vaccine development","volume":"13","author":"Bigay","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0150","doi-asserted-by":"crossref","first-page":"10708","DOI":"10.1073\/pnas.1408677111","article-title":"Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs","volume":"111","author":"Kim","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.12.052_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111359","article-title":"Spike protein-independent attenuation of SARS-CoV-2 Omicron variant in laboratory mice","volume":"40","author":"Liu","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.vaccine.2023.12.052_b0160","article-title":"SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup","volume":"57","author":"Stadlbauer","year":"2020","journal-title":"Curr Protoc Microbiol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0165","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 Virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.052_b0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248348","article-title":"Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2","volume":"16","author":"Neerukonda","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.12.052_b0175","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.chom.2021.03.002","article-title":"SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines","volume":"29","author":"Shen","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.vaccine.2023.12.052_b0180","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.12.052_b0185","doi-asserted-by":"crossref","first-page":"15194","DOI":"10.1073\/pnas.1821317116","article-title":"Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics","volume":"116","author":"Winarski","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2023.12.052_b0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.052_b0195","article-title":"Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters","volume":"13","author":"Liu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.12.052_b0200","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2023.12.052_b0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molimm.2011.11.006","article-title":"Possible allelic structure of IgG2a and IgG2c in mice","volume":"50","author":"Zhang","year":"2012","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181578","article-title":"Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens","volume":"12","author":"Tan","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.12.052_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01166-21","article-title":"Enhanced in vitro and in vivo potency of a T cell epitope in the Ebola virus glycoprotein following amino acid replacement at HLA-A*02:01 binding positions","volume":"96","author":"Chabot","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0220","article-title":"Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis","volume":"8","author":"Kirchdoerfer","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.12.052_b0225","doi-asserted-by":"crossref","first-page":"12201","DOI":"10.1128\/JVI.06048-11","article-title":"A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge","volume":"85","author":"Bolles","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0230","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.immuni.2021.06.018","article-title":"COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge","volume":"54","author":"DiPiazza","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2023.12.052_b0235","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01034-22","article-title":"SARS-CoV-2 virus culture, genomic and subgenomic RNA load, and rapid antigen test in experimentally infected Syrian hamsters","volume":"96","author":"Zhang","year":"2022","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0240","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqac004","article-title":"Polymer formulated self-amplifying RNA vaccine is partially protective against influenza virus infection in ferrets","volume":"3","author":"McKay","year":"2022","journal-title":"Oxf Open Immunol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0245","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jconrel.2021.08.029","article-title":"Polymeric and lipid nanoparticles for delivery of self-amplifying RNA vaccines","volume":"338","author":"Blakney","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.vaccine.2023.12.052_b0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.omtn.2022.11.024","article-title":"Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines","volume":"31","author":"Tregoning","year":"2023","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.vaccine.2023.12.052_b0255","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1128\/JVI.01281-09","article-title":"Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB\/c mice: CD4+ T cells are important in control of SARS-CoV infection","volume":"84","author":"Chen","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0260","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2023.12.052_b0265","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq7647","article-title":"CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques","volume":"7","author":"Liu","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.12.052_b0270","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","article-title":"The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection","volume":"186","author":"Arieta","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2023.12.052_b0275","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2023.12.052_b0280","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.ymthe.2020.11.011","article-title":"Innate inhibiting proteins enhance expression and immunogenicity of self-amplifying RNA","volume":"29","author":"Blakney","year":"2021","journal-title":"Mol Ther"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23014986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:20:48Z","timestamp":1777537248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23014986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0264410X23014986"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.052","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.12.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}